Tidal Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 9

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $470M

Tidal Therapeutics General Information

Description

Operator of a preclinical-stage company intended to utilize a novel mRNA-based approach to in vivo reprogramming of immune cells. The company focuses on developing nanoparticles that deliver mRNA to reprogram immune cells inside the body with applications in oncology and immune diseases, thus providing the healthcare industry with pre-clinical programs for cancer indications.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 700 Main Street
  • Cambridge, MA 02139
  • United States
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Acquirer
Sanofi
Vertical(s)
Corporate Office
  • 700 Main Street
  • Cambridge, MA 02139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tidal Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 09-Apr-2021 $470M Completed Pre-Clinical Trials
3. Early Stage VC 01-Jan-2020 Completed Pre-Clinical Trials
2. Seed Round 01-Jul-2019 Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Tidal Therapeutics’s complete valuation and funding history, request access »

Tidal Therapeutics Patents

Tidal Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024397704-A1 Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof Pending 13-Dec-2023
EP-4824036-A1 Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof Pending 13-Dec-2023
US-20250205169-A1 Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof Pending 13-Dec-2023
WO-2025128902-A1 Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof Inactive 13-Dec-2023
WO-2024163905-A1 Hsc-specific antibody conjugated lipid nanoparticles and uses thereof Inactive 03-Feb-2023 A61K47/6929
To view Tidal Therapeutics’s complete patent history, request access »

Tidal Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tidal Therapeutics Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
AbbVie Ventures Corporate Venture Capital Minority
LabCentral Accelerator/Incubator
MRL Ventures Fund Corporate Venture Capital Minority
Mission BioCapital Venture Capital Minority
Myeloma Investment Fund Not-For-Profit Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Tidal Therapeutics FAQs

  • When was Tidal Therapeutics founded?

    Tidal Therapeutics was founded in 2019.

  • Where is Tidal Therapeutics headquartered?

    Tidal Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Tidal Therapeutics?

    Tidal Therapeutics has 9 total employees.

  • What industry is Tidal Therapeutics in?

    Tidal Therapeutics’s primary industry is Drug Delivery.

  • Is Tidal Therapeutics a private or public company?

    Tidal Therapeutics is a Private company.

  • What is the current valuation of Tidal Therapeutics?

    The current valuation of Tidal Therapeutics is .

  • What is Tidal Therapeutics’s current revenue?

    The current revenue for Tidal Therapeutics is .

  • Who are Tidal Therapeutics’s investors?

    AbbVie Ventures, LabCentral, MRL Ventures Fund, Mission BioCapital, and Myeloma Investment Fund are 5 of 6 investors who have invested in Tidal Therapeutics.

  • When was Tidal Therapeutics acquired?

    Tidal Therapeutics was acquired on 09-Apr-2021.

  • Who acquired Tidal Therapeutics?

    Tidal Therapeutics was acquired by Sanofi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process